We are not trying to embrace the boundless, and we do not manufacture cure-everything drugs. We focus only on the most essential, and we are trying to do this better than others do.

Materia Medica entered the market in 1993, and by 2000 it was manufacturing 21 products in 4 dosage forms. Currently, the company has focused its attention on developing new class of drugs.

Our company is equipped with the most up-to-date GMP compliant facilities. In the process of manufacture, we use up-to-date drug manufacturing, pre-packing and packaging technology.

We manufacture safe drugs, that’s why all our products are recommended not only for adults, but also for children.

Materia Medica is one of major pharmaceutical companies in Russia, having sixth largest output.

In Europe, we are the fourth largest company engaged in manufacturing drugs based on ultra low concentration of active substances.

The safety and efficacy of our products have been clinically evidenced. We are guided by facts and by results of many years of research conducted in cooperation with leading research institutes.

We were the first to carry out systemic research of ultra diluted solutions. The phenomena was discovered in the course of research and became the foundation for a new class of drugs based on ultra low doses of antibodies to endogenous regulators.

For more than 15 years the company has been conducting experimental and clinical studies, cooperating with leading research centers in Russia and abroad.